Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman

$PHIO
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PHIO alert in real time by email

MARLBOROUGH, Mass., Sept. 29, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, today announced the appointment of Robert Bitterman as interim Executive Chairman of the Board of Directors (the "Board"). As Executive Chairman, Mr. Bitterman will assume the duties of principal executive officer and principal financial officer and will lead all aspects of the Company's operations. Mr. Bitterman has served as a director on the Company's Board since 2012 and brings 25 years of executive leadership experience in the pharmaceutical and biologic life science industry coupled with prior experience in senior financial and investor relations roles.

Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg

The Company is also pleased to announce the appointment of Robert Ferrara as Lead Independent Director of the Board.  Mr. Ferrara currently serves as the Chairman of the Audit Committee of the Board. With his appointment, Mr. Ferrara will assume the duties and responsibilities of Lead Independent Director. Mr. Ferrara has served as a director on the Company's Board since 2019 and has held numerous senior executive level financial positions in both domestic and international public and private companies in a variety of industries, including pharmaceuticals and life sciences. Mr. Ferrara is a Certified Public Accountant and earned a BS degree in accounting from Lehigh University.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. The Company's goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.

Contact Phio Pharmaceuticals Corp.

ir@phiopharma.com 

Investor Contact

Ashley R. Robinson 

LifeSci Advisors

arr@lifesciadvisors.com 

Cision View original content:https://www.prnewswire.com/news-releases/phio-pharmaceuticals-announces-appointment-of-robert-bitterman-as-executive-chairman-301636146.html

SOURCE Phio Pharmaceuticals Corp.

Get the next $PHIO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PHIO

DatePrice TargetRatingAnalyst
More analyst ratings

$PHIO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

    Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme

    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

    Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present its proprietary INTASYL siRNA technology and its on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio is committed to the pursuit of cancer free

    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

    Registration Link for Presentation and live Q&A to take place, Wednesday January 29, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present its proprietary INTASYL siRNA technology and an update on its on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio is committed to the pursuit

    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PHIO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PHIO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PHIO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PHIO
SEC Filings

See more

$PHIO
Leadership Updates

Live Leadership Updates

See more
  • Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

    Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme

    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

    Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2024 and provided a business update.Recent Corporate UpdatesThe Phase 1b clinical trial for our lead product candidate, PH-762, received a positive safety recommendation from the Safety Monitoring Committee (SMC). There were no dose-limiting toxicities, or clinically relevant treatment-emergent adverse events in the initial cohort receiving intratumora

    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Phio Pharmaceuticals Announces New Chief Financial Officer

    Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the appointment of Robert M. Infarinato to the position of vice president and chief financial officer effective August 1, 2024. He will serve in the capacity of Principal Financial Officer including responsibility for accounting, finance, treasury, investor relations and administration. Mr. Infarinato comes to Phio with more than 20 years of financial and accounting leadership experience. He most recen

    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PHIO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more